In tablet manufacturing suites operating at ≤ 60% relative humidity, azithromycin amine is rarely fed directly to the hopper of a rotary press. The API exhibits a Hausner ratio above 1.35 and a Carr index above 25 when sourced as flocculent crystalline powder from the 9a-aza synthesis route. Direct compression is therefore rejected for tablet strengths above 100 mg due to die-fill inconsistency exceeding 5% RSD. Wet granulation with aqueous polyvinylpyrrolidone K30 at 2.5–4.0% w/w of dry granule mass is the default route. Granulation is performed in a high-shear mixer equipped with a 10 L bowl and side-chopper at 1,500 rpm impeller speed and 2,500 rpm chopper speed. The end-point is determined by power consumption torque of 12–15 Nm at 25 ± 2°C. The wet mass is passed through a 1.0 mm sieve and dried in a fluid-bed dryer at inlet air 60–65°C, with product temperature controlled below 45°C to avoid degradation of the desosamine sugar moiety. Drying is terminated at loss-on-drying of 1.5–2.0% determined by halogen moisture balance at 105°C. Granule sieve profile after dry milling through 0.8 mm screen: ≥ 85% between 20 mesh and 60 mesh, fines below 100 mesh limited to ≤ 10%.

Tablet compression follows in a 19-station rotary press with precompression force of 4–6 kN and main compression force of 8–14 kN. Tablet hardness is maintained at 80–120 N measured by diametral crush. Friability is below 1.0% per USP <1216> after 100 rotations. The formulation requires dibasic calcium phosphate dihydrate (Emcompress) at 30–50% w/w as the filler because lactose induces Maillard-type browning with the secondary amine functionality of azithromycin amine. Pregelatinized starch at 10–20% w/w provides binding capacity. Crospovidone at 2% w/w and croscarmellose sodium at 4% w/w are split intragranular/extragranular at 60/40 ratio to balance disintegration onset against dissolution plateau. Magnesium stearate at 1.0–1.5% w/w is blended for 3–5 minutes in the final mixing step; lubrication beyond 8 minutes increases dissolution variability to above 10% RSD. Sodium lauryl sulfate at 0.1–0.3% w/w is included as a wetting agent to counter the hydrophobic surface of the API. Dissolution release limits per USP azithromycin tablets monograph use 900 mL of 0.1 N HCl with Apparatus II (paddle) at 50 rpm and 37 ± 0.5°C; Q is 80% at 30 minutes. Method transfer to pH 5.0 acetate buffer is implemented when the aqueous film coat delays tablet wetting beyond 5 minutes; published degradation rate constants show azithromycin amine loses 10% potency within 15 minutes in 0.1 N HCl at 37°C, requiring dissolution sampling intervals no longer than 5 minutes for accurate profile interpretation. Batch-to-batch hardness variation above 10% RSD occurs when granule moisture exceeds 2.0% entering the press. Film coating is applied with Opadry II aqueous dispersion at 3–4% weight gain in a 36-inch perforated pan at inlet air 65–70°C, exhaust 45–50°C, spray rate 10–15 g/min/kg tablet load, and pan speed 4–6 rpm; coating efficiency below 95% requires nozzle-to-bed distance adjustment to 8–10 cm.

Stability-driving impurities in tablet dosage forms are N-demethyl azithromycin and decladinosyl azithromycin. Both are hydrolysis products favored at pH below 4.0 and above 9.0. ICH Q3D elemental impurity assessment starts with Class 1 metals: As, Pb, Cd, Hg; control is achieved by vendor qualification of the API at permitted daily exposure limits per ICH Q3D Table 1. Residual solvent compliance follows USP <467> Option 1, with methylene chloride and methanol levels quantitated from the final granulation because the granulation solvent displaces API-sourced residues. Operational boundary: compression is halted if ambient RH exceeds 60% to prevent punch-face sticking and hardness drift below 50 N.

Why Does Capsule Filling Demand a Two-Stage Blend Optimization for Azithromycin Amine?

Batch records from production-scale capsule filling lines show that single-stage blending rarely achieves uniformity below 5% RSD when API loading falls between 10% and 25% w/w. The failure mode is dry segregation driven by the high aspect ratio of azithromycin amine needles. The blend is therefore assembled in two stages. Stage one combines API with microcrystalline cellulose PH102 at 25:75 ratio in a 50 L bin blender at 12 rpm for 10 minutes; this stage is overtorque-protected to 1.5 Nm. Stage two transfers the pre-blend into a 250 L double-cone blender, adds pregelatinized starch 5–10% w/w and remaining MCC PH102, and blends at 10 rpm for an additional 10 minutes. Blend uniformity per USP <905> is tested at 10 sampling locations; acceptance is RSD ≤ 5.0% and all individual values within 90–110% of label claim. The two-stage approach is mandatory because the API has poor adhesive mixing characteristics and migrates to the void fraction between larger diluent particles during cone rotation.

Capsule shell selection is dictated by cross-linking risk. Hard gelatin shells develop pellicle formation when azithromycin amine oxidative degradation generates trace aldehydes, which cross-link lysine residues in gelatin. Hydroxypropyl methylcellulose capsules (Vcaps Plus or Qualicaps) are specified for long-term storage in ICH Zone IVb. Moisture of the final blend is held at KF ≤ 3.0% before encapsulation on a Zanasi 12E intermittent encapsulator at 20,000–25,000 capsules/h. Fill weight RSD is controlled to ±3% using tamping pins set at 30–35 mm penetration depth with 3 tamps per filling cycle. Empty capsule weight variation is pre-checked on 100 shells; acceptance is RSD ≤ 1.5%. Net fill weight per capsule for a 250 mg strength unit is 295–315 mg, with adjustment by a dosator disk diameter sized to produce a slug height of 10–12 mm. Weight variation follows USP <905> criteria for capsules; content uniformity is tested on 10 units with acceptance value ≤ 15 per USP <905>. Dissolution from capsule products uses USP Apparatus I (basket) at 100 rpm in 900 mL of 0.1 N HCl at 37 ± 0.5°C; Q is 75% at 30 minutes. Cross-check with USP Apparatus II is not performed because capsule shells bind to the paddle shaft under shear, producing non-integer dissolution curves. Disintegration per USP <701> is NMT 15 minutes in water at 37°C without discs; HPMC shells often show a 2–3 minute delay in initial rupture compared to gelatin, which is accounted for in the dissolution Q-time.

Ion exchange incompatibility is a processing alert. Azithromycin amine is a weak base with pKa values of 8.74 and 9.45; when blend pH exceeds 7.5, the un-ionized form partitions into capsule shell wicking layers. Published data for this specific configuration in HPMC shells is limited; blending with acidulants is therefore not performed without a stability protocol that includes 6-month accelerated data at 40°C/75% RH.

Granule sachet products containing azithromycin amine are produced on top-spray fluid bed systems when immediate reconstitution in water is required for pediatric or geriatric administration. The batch size reported here is 2 kg of dry solids on a GPCG-2 unit. The binder is hydroxypropyl methylcellulose E5 at 3% w/v dissolved in purified water at 70°C and cooled to 25°C before spraying. Spray rate is 8–12 g/min via a 1.0 mm two-fluid nozzle at atomization air 1.5–2.0 bar. Inlet air temperature is set at 65–70°C and product temperature is maintained at 38–42°C by continuous adjustment of inlet air. Spray phase duration is 25–35 minutes; after spraying, drying continues at 55°C product temperature until LOD reaches 0.8–1.5%. Final granule bulk density is 0.45–0.55 g/mL, tapped density 0.55–0.65 g/mL, with a Hausner ratio of 1.15–1.25, indicating acceptable flow. Sieve analysis targets ≥ 85% retained between 20 mesh and 60 mesh and fines through 100 mesh NMT 10%. Sachet filling is performed on a Bosch horizontal form-fill-seal machine operating at 30 sachets/min with a fill weight of 2.0 g ± 5%. Barrier material is ALU/ALU 4-ply laminate with oxygen transmission rate < 0.1 cm³/m²/24 h and water vapor transmission rate < 0.1 g/m²/24 h at 40°C/75% RH. Reconstitution time in 20 mL water at 20°C is NMT 60 seconds per Ph. Eur. 2.9.1. The granule product does not contain disintegrant because disintegration and dissolution occur only after reconstitution; using intragranular crospovidone in sachets would generate a viscous gel layer upon reconstitution and raise the sedimentation volume of the product.

Injectable-Grade Azithromycin Amine Assembly: Terminal Sterilization, Lyophilization, and Container Closure Integrity

Sterile production begins with Water for Injection of conductivity ≤ 1.3 µS/cm at 25°C and total organic carbon below 500 ppb. Azithromycin amine is dissolved at a concentration equivalent to 100 mg/mL azithromycin base, with pH adjustment to 6.2–6.8 using citric acid monohydrate at 1.0–2.5 mg/mL or 0.1 N sodium hydroxide. Dissolution is performed under nitrogen overlay at 20–25°C in a 316L stainless steel jacketed vessel with bottom-mounted magnetic drive agitator at 200–300 rpm. Terminal heat sterilization is not applicable because azithromycin amine degrades by 5% within 60 minutes at 80°C in aqueous solution. The sterilizing route is therefore 0.22 µm PVDF membrane filtration (Pall Fluorodyne II DBLP cartridge) at 2.5–3.5 L/min/m² membrane area. Filter integrity is tested before and after each filling run by bubble point at ≥ 3,200 mbar for the 0.22 µm grade. Maximum filtered solution hold time is 8 hours at 2–8°C, with bioburden verification ≤ 10 CFU/100 mL immediately before filtration per EU GMP Annex 1 paragraph 5.31.

The filtered solution is filled into 10 mL Type I borosilicate glass vials (Schott Fiolax clear) at 5.0 mL per vial, delivering 500 mg azithromycin base per unit. Filling is performed on a peristaltic piston pump aseptic line under laminar air flow at ISO 5, with in-process fill volume check by gravimetric means every 15 minutes; acceptance is 5.00–5.15 mL. Lyophilization is performed in a shelf freeze dryer with 5 m² shelf area. The cycle program is: freezing ramp at −1°C/min to −40°C, hold for 4 hours; primary drying at shelf temperature −20°C with chamber pressure 80–100 mTorr for 36–48 hours; secondary drying at shelf 25–30°C with pressure 50–80 mTorr for 12–20 hours. The primary drying endpoint is determined by comparative Pirani vs. capacitance manometer pressure differential of < 5 mTorr sustained for 2 hours. The glass transition temperature of the maximally freeze-concentrated amorphous phase (Tg') for the citric acid-buffered formulation is reported in published lyophilization literature at approximately −28°C to −33°C; primary drying is therefore deliberately maintained below this value to prevent macrocollapse. Stopper closure uses 20 mm Dalkyo V9213 bromobutyl rubber stoppers with FluroTec coating under partial vacuum of 500–600 mbar nitrogen. Container closure integrity is verified by dye ingress per USP <1207> using 0.1% methylene blue at 25°C for 30 minutes; acceptance is no visible dye penetration.

Release testing for injectable product is governed by the azithromycin injection monograph and general chapters. Sterility is tested per USP <71> membrane filtration with 14-day incubation at 20–25°C (tryptic soy broth) and 30–35°C (fluid thioglycollate medium). Bacterial endotoxins are quantitated per USP <85> kinetic chromogenic method; acceptance is NMT 0.17 EU/mg of azithromycin. Particulate matter is tested per USP <788> Light Obscuration test after reconstitution; acceptance is NMT 6000 particles ≥ 10 µm and NMT 600 particles ≥ 25 µm per container. pH after reconstitution with 4.8 mL SWFI is 6.0–7.0 per USP <791>. Residual moisture by Karl Fischer coulometric titration per USP <921> is NMT 2.0%. Potency by HPLC per the USP monograph is 90.0–110.0% of label claim. Related substances per Ph. Eur. monograph 1649 are controlled with total impurities ≤ 2.0% and any unspecified individual impurity ≤ 0.5%. Reconstitution time is visually confirmed complete within 120 seconds with manual shaking. Osmolality of the 100 mg/mL reconstituted solution is approximately 340–380 mOsm/kg, which is hypertonic; direct IV push is therefore contraindicated and literature-based dilution to 1–2 mg/mL in 0.9% NaCl or 5% Dextrose is required before infusion.

Reconstitution at the point of care uses 4.8 mL sterile Water for Injection into the 500 mg vial. The resulting 100 mg/mL solution is diluted for IV infusion to 1.0–2.0 mg/mL in 0.9% sodium chloride or 5% dextrose. Infusion duration is 60–180 minutes. Compatibility studies published in injectable drug reference databases demonstrate precipitation risk when azithromycin amine is mixed in the same IV line with aminoglycosides, heparin sodium, or high-chloride buffers at pH below 5.0. The reconstituted 100 mg/mL solution is held no longer than 24 hours at 25°C or 72 hours at 2–8°C; diluted 1–2 mg/mL infusion solutions are held no longer than 24 hours at 25°C or 7 days at 2–8°C in polysorbate-free PVC-free containers. Extractable testing per ICH Q3E draft guidance is performed on vial-stopper-configuration with 3 solvent systems: 50% ethanol/water, 0.9% NaCl pH 3, and 0.9% NaCl pH 9; semicarbazide migration from bromobutyl closure system is monitored by LC-MS at reporting threshold 0.5 µg/vial.

Oral Suspension Vehicle Selection and Controlled Flocculation

Controlled flocculation is achieved in azithromycin amine oral suspensions by pairing the cationic drug surface with an anionic polysaccharide network. The bitter threshold of the API at neutral pH dictates an API particle size D90 below 30 µm in the dried powder blend. The vehicle is sucrose at 80% w/v or sorbitol at 60% w/v for diabetic-adjusted formulations. Suspending agents are xanthan gum at 0.3–0.5% w/v combined with hydroxypropyl methylcellulose E5 at 0.1% w/v as a protective colloid. Preservative load is sodium benzoate at 0.2% w/v with benzoic acid to pH 4.5–5.0; at this pH, 70–75% of benzoic acid remains un-ionized based on pKa of 4.2, preserving antimicrobial activity per USP <51> challenge test. Buffer is anhydrous sodium phosphate 10–20 mM; exceeding 30 mM causes rapid settling due to ionic strength compression of the electric double layer. The particle zeta potential is +15 to +25 mV at pH 5.0, providing electrostatic repulsion that counters Van der Waals attraction; the suspension exhibits plastic flow with yield value of 0.5–1.5 dyn/cm² measured on a controlled-stress rheometer at 25°C. Viscosity is 200–400 cP on a Brookfield LV viscometer, spindle 2, at 30 rpm and 25°C. Sedimentation volume ratio F is maintained at 0.95 ± 0.02; values below 0.80 require reformulation because cake formation prevents redispersibility within 10 inversion cycles.

The dried powder for reconstitution is filled into 60 mL amber PET bottles with 32 mm child-resistant closures lined with EPE induction seals. Fill volume corresponds to 50 mL reconstituted suspension at 100 mg/5 mL or 200 mg/5 mL. Reconstituted suspension stability is 14 days at 2–8°C and 10 days at 25°C, with potency retest on days 0, 3, 7, 10, and 14; azithromycin amine in vehicle degrades by the pH-dependent hydrolysis of the cladinose sugar, with pseudo-first-order rate constant of 0.003 day⁻¹ at 5°C and 0.015 day⁻¹ at 25°C in published stability literature. Microbiological quality per USP <1111> requires total aerobic microbial count ≤ 100 CFU/mL and total yeast and mold ≤ 10 CFU/mL. Dosing is by 10 mL graduated syringe; administration with antacids containing magnesium or aluminum hydroxide reduces Cmax of azithromycin by 24–33% based on published single-dose pharmacokinetic interaction studies at 250 mg oral dose. The product is not to be administered simultaneously with iron sulfate suspension because insoluble azithromycin-iron complexes form at pH 3.0–4.0 in the gastric environment, reducing bioavailability.

With direct compression specified for dispersible tablet manufacture, the formulation requires a three-component balancing act between compact hardness, dispersion time, and taste masking. The API is used at 40–80% w/w to achieve 100 mg or 250 mg per unit. Crospovidone at 8% w/w plus croscarmellose sodium at 3% w/w extragranular provide the rapid water uptake needed for dispersion. Mannitol SD200 at 30–45% w/w serves as both diluent and cooling sensation vehicle. Microcrystalline cellulose PH105 at 10–15% w/w provides compactibility at low compression force; stearic acid at 2% w/w is the lubricant, replacing magnesium stearate because magnesium combined with mannitol forms a hydrophobic film that can raise dispersion time above 60 seconds. Compression runs on a 27-station rotary press at 6–10 kN producing 12 mm round flat-faced bevel tablets of 30–50 N hardness. Dispersion testing per Ph. Eur. 2.9.1 requires complete passage through a 710 µm sieve after 3 minutes in 500 mL water at 15–25°C; the product specification tightens this to NMT 60 seconds. Taste masking uses sucralose at 1.5–2.5% w/w combined with orange cream flavor at 2–3% w/w; bitterness breakthrough occurs when API content exceeds 80% w/w because the sucralose sweetening threshold at 2.5% w/w is 300–400 times sucrose but is insufficient to block the cationic amine taste at high loading. Container is 30-count ALU/ALU blister with desiccant maintaining internal RH below 30% through 24 months at ICH Zone IVb. Elemental impurity limits apply per ICH Q3D for oral products: Class 1 metals As, Pb, Cd, Hg are controlled by API vendor to permitted daily exposure values based on 1,000 mg azithromycin daily dose.